News | April 17, 2026
NIFTY Pharma shows stable trend amid cautious market sentiment
Muted movement reflects consolidation phase as investors await earnings triggers
Muted movement reflects consolidation phase as investors await earnings triggers
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
The stability is led by healthy demand in the domestic and emerging markets
Post normalisation of high growth months of April and May this year the average IPM growth from June to August this year stood at 15.2 % YoY : Ind-Ra reports
Derived from rice bran wax, Licocare RBW products offer a renewable solution with a substantially lower carbon footprint than conventional montan waxes
First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors
The newly licensed platform enables precise control over both the drug-to-antibody ratio and payload attachment sites in single- and dual-payload ADCs
The company highlighted continued demand strength and pricing resilience despite global disruptions
India already has talent, digital infrastructure, entrepreneurial energy, clinical expertise, and policy momentum. The next phase demands coordinated execution and building institutions that can hold the ecosystem together over time
Subscribe To Our Newsletter & Stay Updated
